Designing of Anti-Cancer Drug Targeted to Bcl-2 Associated Athanogene (BAG1) Protein by Amit Kumar et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
31 
Designing of Anti-Cancer Drug Targeted to  
Bcl-2 Associated Athanogene (BAG1) Protein 
Amit Kumar, Kriti Verma and Amita Sinha 
 Department of Bioinformatics and MolecularBiology, 
Bioaxis DNA Research Centre, Hyderabad, 
India 
1. Introduction 
Cancer is a disease of uncontrolled cell growth in tissues. This growth may lead to 
metastasis, which is the invasion of adjacent tissue and infiltration beyond the site of 
initiation. Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor 
genes. Nearly 10-30% of all adenocarcinomas are due to the mutations in the K-ras proto-
oncogene. [1] Function and regulation of Bcl-2 proteins depends upon their interaction with 
other non-family member proteins, including NIP1, NIP2, NIP3, p53 BP2, Raf-1, CED-4, 
calcineurin, R-Ras and Bag-1 to form homo and hetero dimmers.[21] Bag1 belongs to the Bcl-
2 associated athanogene (BAG) family of multifunctional proteins. This widely expressed 
protein interacts with a number of signalling molecules (including Bcl2, HGF receptor and 
Raf1) as it regulates signalling molecules in pathways involving cell survival, growth and 
differentiation. [13] Bcl2 associated athanogene (BAG1) protein is involved in regulation of 
the Ras/Raf signal transduction pathway.  Of particular relevance to tumour cells, BAG-1 
interacts with the anti-apoptotic BCL-2 protein, various nuclear hormone receptors the 70 
kDa heat shock proteins, Hsc70 and Hsp70; and serine/threonine kinase. Raf-1 which plays 
an important role in MAPK pathway.[2][3][4] Recent studies have shown that BAG-1 
expression is frequently altered in malignant cells, and BAG-1 expression may have clinical 
value as a prognostic or predictive marker for various cancer types including breast cancer, 
prostate cancer and lung cancer.[6][7][8] (Fig 1) Interaction with chaperones may account for 
many of the pleiotropic effects associated with BAG-1 over expression. The finding that 
BAG-1 can independently associate with Raf-1 or Bcl-2 provides at least two mechanisms by 
which BAG-1 promotes cell survival. [20] 
Bcl2-associated athanogene (BAG) family proteins participate in a wide variety of cellular 
processes to regulate growth control pathways, including cell survival (stress response), 
proliferation, migration, signalling and apoptosis (Fig 2).[2][5][18] This family of co-
chaperones functionally regulates signal transduction proteins Raf/MEK/ERK and 
transcription factors important for cell stress responses, apoptosis, proliferation, cell 
migration and hormone action. In response to stress, they bind to heat shock proteins 
HSP70/HSC70 coordinating cell growth signals, by down-regulating the activity of 
serine/threonine kinase, Raf-1, which plays an important role in MAPK pathway. [5][9] The 
proteins show anti-apoptotic activity and increase the anti-cell death function of BCL-2 
induced by various stimuli. Over expression of BAG-1 suppresses activation of caspases and 
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apoptosis induced by a very broad range of agents in different cell types, for example 
chemotherapeutic agents, radiation and growth factor withdrawal. Therefore, in addition to 
contributing to reduced cell death in cancer development, BAG-1 may also contribute to 
resistance to important therapeutic modalities.  
 
 
 
Fig. 1. BAG1 expression in normal and diseased human tissues. 
BAG-1 proteins are expressed as multiple isoforms generated by alternate translation 
initiation from a single mRNA. Translation of the major human BAG-1 isoform, BAG-1S, 
initiates at an internal AUG codon, whereas of the larger BAG-1L (p50) and BAG-1M 
proteins translation begins upstream at CUG and AUG codons, respectively.[6][9] Hence, 
the proteins share a common C-terminus. However, the larger isoforms have additional N-
terminal sequences. Various domains have been identified within BAG-1 proteins. [14] A 
potential nuclear localisation signal (NLS) within the unique N-terminal domain of BAG-1L 
has been identified. However, BAG-1S and BAG-1M lack this sequence. BAG-1S is largely 
located in the cytoplasm in contrast to BAG-1M which partitions between the nucleus and 
cytoplasm. [8] 
At the carboxy terminal of all BAG-1 isoforms there is a conserved region of about 110 
amino-acids, named as the ‘BAG domain’, which binds and regulates Hsp70/Hsc70 
molecular chaperones. [8][23] BAG domains are present in Bcl-2-associated athanogene 1 
and silencer of death domains.   
The crystal structure of the BAG domain revealed that it consists of three anti-parallels α 
helices. In the BAG domain the first and the second α-helices interact with the 
serine/threonine kinase Raf-1 and the second and third α-helices interact with the ATP-
binding pocket of Hsc70/Hsp70. Therefore, Raf-1 and Hsp70/Hsc70 have partially 
overlapping sites and their binding is competitive. [2] [8] 
BAG-1 promotes cell growth by binding to and stimulating Raf-1 activity. The binding of 
Hsp70 to BAG-1 diminishes Raf-1 signalling and inhibits subsequent events, such as DNA 
synthesis, as well as arrests cell cycle. When cellular levels of Hsp70 are elevated during 
stress, or in cells conditionally over expressing Hsp70, Bag1-Raf-1 is displaced by Bag1-
Hsp70, and DNA synthesis is arrested.[5][10] Thus, BAG-1 has been suggested to function as 
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a molecular switch that controls cells to proliferate in normal conditions but become 
quiescent under a stressful environment.[16] 
The C-terminus of the BAG domain is also a site of interaction with Bcl-2 which provides a 
supra-additive anti-apoptotic effect. The BAG-1 protein shares no significant homology with 
Bcl-2 or other Bcl-2 family proteins, which can form homo- and heterodimers. [11] 
All BAG-1 isoforms also contain an ubiquitin-like domain (ULD), similar to ubiquitin and 
ubiquitin-like proteins that appears to be essential for at least some biological effects[8][7][15]. 
Although the precise function of the ULD in BAG-1 is unknown, BAG-1 isoforms are very 
stable proteins suggesting that they are not generally targets for degradation by the 
ubiquitin/proteasome system and are not covalently attached to other proteins. 
2. Role of BAG1 and Bcl2 in apoptosis 
Bcl-2 is an anti-apoptotic protein located mainly on the outer membrane of mitochondria. It 
has been found that over-expression of Bcl-2 inhibits cells from undergoing apoptosis in 
response to a various stimuli. [12] The members of the Bcl-2 family share one or more of the 
four characteristic domains of homology entitled the Bcl-2 homology (BH) domains (named 
BH1, BH2, BH3 and BH4).[11][13] The BH domains are known to be crucial for its function, 
as deletion of these domains via molecular cloning affects survival/apoptosis rates. The 
anti-apoptotic Bcl-2 proteins, such as Bcl-2 and Bcl-xL, conserve all four BH domains. Bcl-2 
interacts with pro-apoptotic proteins BAX and BAK. The hydrophobic unit of Bcl-2 forms a 
heterodimer with the amphipathic unit of BAX and BAK. This heterodimer formation 
inhibits release of cytochrome c from the mitochondria and prevents activation of caspases. 
The protein encoded by BAG1 gene binds to BCL2 and is referred to as BCL2-associated 
athanogene. It enhances the anti-apoptotic effects of BCL2. [12][13] 
 
 
Fig. 2. Interaction of BAG1 protein with other proteins and cellular components. [8] 
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3. Role of Raf-1/ MAPK pathway in cancer 
The pathways regulated by BAG-1 play key roles in the development and progression of 
cancer and determining response to therapy. The extracellular signal-related kinase (ERK), 
among the MAPK pathways, plays a key role in promotion of cellular proliferation, 
survival, and metastasis, this pathway directly affects the initiation and progression of 
human tumors.   This pathway has been found to be activated in numerous cancer types 
without obvious genetic mutations. Cell lines derived from various organs such as pancreas, 
colon, lung, ovary and kidney have been reported to show a high degree of MAP kinase 
activation as observed in 50 tumor cell lines. However, it ihas been found that the 
constitutive activation of MAP kinases in tumor cells is not due to the disorder of MAP 
kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling 
molecules upstream of Ras.[3] 
The Ras/Raf/MEK/ERK pathway  also interacts with the p53 pathway thereby regulating 
the activity and subcellular localization of BCl2 family proteins (Bim, Bak, Bax, Puma and 
Noxa). Thus the Raf/MEK/ERK pathway has different effects on growth, prevention of 
apoptosis, cell cycle arrest and induction of drug resistance in cells of various lineages.[3][4] 
4. Methodology used in present study 
The strategy used in this project is to target the first alpha helix of the BAG domain. Binding 
of a ligand to the first alpha helix provides two simultaneous scenarios i.e. firstly it blocks 
the site for Raf1 binding and thus blocks the MAPK pathway. Secondly, it makes the second 
and third alpha helix available for Hsp70 binding. Binding of Hsp70 to BAG1 protein 
renders the heat shock protein inactive as BAG1 has been found to have inhibitory effect on 
Hsp proteins. This shall produce pseudo stress conditions and attenuate DNA synthesis and 
cellular proliferation. 
Thus, the aim of the present study is to design a drug, targeted to the first alpha helix of 
‘BAG Domain’ of BAG1 protein that binds to the competitive binding site of Raf1 and Hsp70 
thereby blocking the binding site of Raf1, making it available for Hsp70 binding and hence 
suppressing its anti-apoptotic activity. The therapeutic goal is to arrest further tumor 
progression and trigger tumor-selective cell death by disrupting the balance between pro-
apoptotic proteins and anti-apoptotic proteins (Fig 3). 
5. Important tools and databases 
NCBI is a primary database majorly used for sequence retrieval and similarity based 
searches. We used NCBI for our sequence retrieval of query protein sequence. BLAST is the 
most widely used sequence similarity search programme. It finds regions of local similarity 
between sequences. In this study protein blast has been extensively used. PubMed database 
was primarily used for literature search including journals, abstracts, full text articles and 
other sources related to the research. PDB is repository for the 3-D structural data of large 
biological molecules, such as proteins and nucleic acids which is obtained by X-ray 
crystallography and NMR spectroscopy. PDB was used to retrieve the 3D structure of the 
protein. Biology Workbench is a web based tool integrated with access to a wide variety of 
analysis and modeling tools. This tool has been used for phylogenetic analysis of the Bag1 
protein sequences. 
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Clustalw is a multiple sequence alignment program that calculates the best match for the 
selected DNA or protein sequences and then lines them up so that the identities, similarities 
and the differences can be seen. Boxshade works by global alignment of all sequence. 
Conserved and similar residues are emphasized by various degrees of shading. KEGG 
database was used for pathway analysis for this Bag1 protein. Genecards has been used in 
this work to get various expression and sequence related information pertaining to proteins 
of the Bag1 protein. In this work all the above programs have been used to obtain the 
peptide recognition pattern for the interpretation of results. 
 
 
 
 
Fig. 3. Flowchart depicting the drug targeted strategy. 
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6. Structure analysis tools 
ProtParam is a tool which allows the computation of various physical and chemical 
parameters for a protein sequence. The computed parameters include the molecular weight, 
theoretical pI, amino acid composition, atomic composition, extinction coefficient, estimated 
half-life, instability index, aliphatic index and grand average of hydropathicity (GRAVY). 
The HNN method was used for secondary structure prediction for Bag1 protein. 
CPHmodels is a web server predicting protein 3D structure by use of single template 
homology modeling. The CPHmodels server predicts protein structure from amino acid 
sequence with respect to distance constraints. CPHmodels is a collection of methods and 
databases consisting of the following tools: CPHmodels was used for tertiary structure 
prediction of Bag1 protein. 
The 3d structure obtained as a pdb file format was viewed using RasMol. 
PRODOM and PROSITE is a comprehensive database of protein domain and families. 
PROSITE offers tools for protein sequence analysis and motif detection. 
STRING is a database of known and predicted protein interactions. 
CASTP (Computed Atlas of Surface Topography of Proteins) is a server that provides 
identification and measurements of surface accessible pockets as well as interior inaccessible 
cavities for proteins and other molecules.  
7. Drug discovery tools 
Drugbank, Pubchem, therapeutic target database (TTD), Tocris are the various databases 
which were searched for potential drug candidates. 
ArgusLab was used as a molecular modelling program to optimize the target receptor 
protein and design a drug targeted to the BAG1 protein. The quantum mechanical 
calculations were performed using the Argus compute server.  
HEX5.1 is an interactive protein docking and molecular superposition program. HEX5.1 was 
used for docking of the selected drug candidate with the BAG1 target protein. 
8. Results and discussion 
BAG1 isoform 1-L sequence was retrieved from NCBI. The protein BAG1-L is 345 amino 
acids in length. Sequence analysis by BLASTp shows that Bag1-L protein showed maximum 
identities with Bos Taurus (83%) followed by Mus musculus (80%). BLAST results of BAG1 
protein compared with other model organisms is shown in Table 1. 
Evolutionary relationship of BAG1 protein among various species was obtained in the form 
of a dendrogram (Fig.4) The query protein was seen to be most closely related to Mus 
musculus and showed a distinct evolutionary relationship with Suberites domuncula. The 
highly conserved regions in the amino acid sequence of BAG1 in protein among various 
model organisms were analysed using Boxshade (Fig. 5). The amino acids Glycine and 
Glutamine were found to be the maximum conserved regions among all the species 
analysed. 
The structural analysis of BAG1-L protein was done by using ProtParam, HNN & CPH.  
Since the GRAVY value is negative (-0.905) it can be inferred from the results that the 
protein is a hydrophobic molecule present at the cell surface.  It is an unstable protein. It 
consists of 40.00% alpha helices and no beta bridges or turns are present. (Fig. 6) Using CPH 
model, the 3D structure of the protein was retrieved in the form of a PDB ID. The PDB ID 
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with the maximum score i.e. 1HX1 was chosen and viewed in Rasmol. (Fig. 7) The PDB ID 
1HX1 shows the 3D structure for two molecules Hsp70 and Bag domain as Chain A (400aa) 
and Chain B (114aa) respectively. The Chain B i.e. Bag domain (receptor) was isolated and 
its energy was optimized to 3734.78 au using ArgusLab. The molecule converged at 298.92 
kcal\mol.  
CASTP was used to find the active pocket in the receptor protein. The amino acid Lysine in 
Chain B (receptor molecule) at position 172 is selected as the target residue for Arguslab 
docking as it is the most hydrophilic residue in the active pocket. 
A number of small molecules that bind to the target were searched by screening libraries of 
potential drug compounds. The toxic effects and pharmacodynamics of the compounds was 
tested by ADME/Tox. The compound Carmustine was chosen out of the drug library as it 
followed the Lipinski’s rule of five and had the best combination of required properties for a 
potential drug candidate. (Table 2) 
The molecule Carmustine was designed in ArgusLab and geometry optimization of the 
drug got converged at energy of 22.2 Kcal\mol. Total energy of the compound converged at 
-101.413 au. 
The drug was docked to the target residue using Arguslab and Hex5.1. In Hex, the drug 
docked to the receptor with an Emax value (Energy) of -94.68 kcal\mol and Emin value of -
166.49 kcal\mol. (Fig. 9) In Arguslab, the drug docked to the target receptor with energy of -
5.51 kcal\mol. 
 
 
 
 
 
 
 
Fig. 4. Dendogram depicting the phylogenetic relationship of Bag1 (Query) protein in Homo 
sapiens with Bag1 protein of other model organisms (humans). 
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Fig. 5. Boxshade showing some of the highly conserved (green) and similar (cyan) pattern 
for Bag1 protein in different model organisms. 
 
 
 
Fig. 6. The secondary structure analysis result of Bag1 by HNN tool. The alpha helices are 
shaded blue, beta sheets are shaded red. 
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Fig. 7. Visualization result of Bag1protein using the tool RASMOL showing the 3D structure 
details. 
 
Fig. 8. STRING analysis of BAG1 protein showing its interaction with other proteins in the 
human. The number of lines represents the strength of interaction. 
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Fig. 9. Docking analysis result of Bag1 protein with the drug Carmustine in Hex5.1. 
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Model 
Organism 
Name 
BLAST 
Results 
Homo sapiens 
GENE ID: 573 BAG1 | BCL2-associated athanogene [Homo sapiens] 
(Over 10 PubMed links) 
 Score = 724 bits (1671), Expect = 0.0, Method: Compositional matrix 
adjust. 
 Identities = 345/345 (100%), Positives = 345/345 (100%), Gaps = 0/345 
(0%) 
Bos taurus 
GENE ID: 613855 BAG1 | BCL2-associated athanogene [Bos taurus] 
 Score = 413 bits (950), Expect = 1e-115, Method: Compositional matrix 
adjust. 
 Identities = 198/236 (83%), Positives = 214/236 (90%), Gaps = 1/236 
(0%) 
Mus musculus 
GENE ID: 12017 Bag1 | BCL2-associated athanogene 1 [Mus musculus] 
(Over 10 PubMed links) 
 Score = 362 bits (831), Expect = 1e-99, Method: Compositional matrix 
adjust. 
 Identities = 172/214 (80%), Positives = 188/214 (87%), Gaps = 0/214 
(0%) 
Gallus gallus 
GENE ID: 420967 BAG1 | BCL2-associated athanogene [Gallus gallus] 
(10 or fewer PubMed links) 
 Score = 310 bits (712), Expect = 8e-85, Method: Compositional matrix 
adjust. 
 Identities = 144/209 (68%), Positives = 179/209 (85%), Gaps = 2/209 
(0%) 
Rattus 
norvegicus 
GENE ID: 297994 Bag1 | BCL2-associated athanogene [Rattus 
norvegicus] 
(Over 10 PubMed links) 
 Score = 497 bits (1145), Expect = 9e-141, Method: Compositional matrix 
adjust. 
 Identities = 250/358 (69%), Positives = 286/358 (79%), Gaps = 13/358 
(3%) 
Dictyostelium 
discoideum 
GENE ID: 8616246 sonA | UAS domain-containing protein 
[Dictyostelium discoideum AX4] (10 or fewer PubMed links) 
 Score = 34.5 bits (102),  Expect = 0.053, Method: Compositional matrix 
adjust. 
 Identities = 17/49 (34%), Positives = 29/49 (59%), Gaps = 1/49 (2%) 
Caenorhabditis 
elegans 
GENE ID: 172373 bag-1 | BAG1 (human) homolog [Caenorhabditis 
elegans] 
(10 or fewer PubMed links) 
 Score = 51.5 bits (160),  Expect = 8e-07, Method: Compositional matrix 
adjust. 
 Identities = 44/145 (30%), Positives = 81/145 (55%), Gaps = 8/145 (5%) 
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Model 
Organism 
Name 
BLAST 
Results 
Suberites 
domuncula 
emb|CAJ65915.1|  BAG family molecular chaperone regulator 1 
[Suberites domuncula] 
Length=258 
 Score = 99.5 bits (324),  Expect = 4e-19, Method: Compositional matrix 
adjust. 
 Identities = 63/186 (33%), Positives = 110/186 (59%), Gaps = 4/186 (2%) 
Brugia malayi 
GENE ID: 6105907 Bm1_55120 | BAG domain containing protein [Brugia 
malayi] 
(10 or fewer PubMed links) 
 Score = 47.1 bits (145),  Expect = 5e-06, Method: Compositional matrix 
adjust. 
 Identities = 57/199 (30%), Positives = 92/199 (46%), Gaps = 8/199 (4%) 
 
 
Table 1. Showing the result of query sequence BLAST with different model organisms. 
 
 
 
 
 
 
 
Table 2. List of various potential drug candidates for binding with Bag domain of Bag 1 
protein. 
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The BAG proteins having anti-apoptotic activity promotes cell growth by binding to and 
stimulating Raf-1 activity. BAG-1 binds to the serine/threonine kinase Raf-1 or 
Hsc70/Hsp70 in a mutually exclusive interaction. The binding of Hsp70 to BAG-1 
diminishes Raf-1 signalling and inhibits subsequent events, such as DNA synthesis, as well 
as arrests the cell cycle. Hence Bag1 plays an important role in the progression of cancers 
when over expressed.  The 345 amino acid long protein sequence of BAG1-L was obtained 
from NCBI and a BLASTp was performed to analyze its evolutionary relationships with 
other counterparts in various model organisms. This was confirmed by the phylogenetic 
analysis done using SDSC workbench. The dendrogram presents that Bag1 had close 
evolutionary relationship with Mus musculus.  
From the primary structure analysis it was concluded that BAG1 protein is a surface protein 
which is hydrophilic in nature. Its secondary structure analysis confirmed that it contains 
more alpha helices and no beta sheets. Its 3D structure was obtained in the form of PDB id 
and viewed in Rasmol. The chain B of PDB structure represents the BAG domain. Various 
confirmatory tools were used for validation of the results. The geometry and energy of the 
BAG domain was optimized in Arguslab.  Using Castp, the active pocket in the BAG 
domain was identified and the most hydrophilic residue in the first alpha helix of the BAG 
domain i.e. LYS at position 242 of BAG1-L protein sequence obtained from NCBI (or 
position 172 in the Chain B of pdb id 1HX1) was selected as the target receptor. 
A drug library was maintained of possible lead compounds that follow the Lipinski rule of 
five and their toxicity and disposition was checked using ADME/TOX. These candidate 
drugs were docked to the target receptor. The drug CARMUSTINE showed the best docking 
result with docking Energy of -5.51kcal/mol.  As the docking (Fig 9) was successful in both 
HEX5.1 and Arguslab it can be concluded that Carmustine can be a potential drug for BAG1 
binding and arresting tumor progression. Further analysis must be performed on this drug 
for use in treatment of cancer. 
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